Summit Therapeutics Inc.
Financials
Valuation Metrics
Summit Therapeutics Inc.'s Market Cap is $14.24B. At end of 2025 it was $13.08B. Ranked #738 of 3,121 in US market (top 24%), #232 of 1,463 on NASDAQ (top 16%), #35 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.24B | US#738/3,121 Sec#35/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-856M | US—/3,121 Sec—/266 |
| Total Assets | $752M | US#2,601/3,121 Sec#125/266 |
| Net Assets | $630M | US#2,082/3,121 Sec#93/266 |
| Employees | 265 | US#2,445/3,121 Sec#117/266 |
| Value | ||
| P/B | 22.60x | US#2,812/3,121 Sec#221/266 |
| FCF Yield | -2.86% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -135.89% | US#2,821/3,121 Sec#212/266 |
| Financial Health | ||
| Debt Ratio | 19.40% | US#223/3,121 Sec#77/266 |
| Total Debt | $20M | US#2,757/3,121 Sec#189/266 |
| FCF | $-407M | US#2,881/3,121 Sec#245/266 |
| Cash | $419M | US#1,184/3,121 Sec#66/266 |
| Current Ratio | 6.96x | US#359/3,121 Sec#112/266 |
| Performance | ||
| 1Y Return | -7.18% | US#1,887/3,121 Sec#187/266 |
| 1M Return | 36.16% | US#23/3,121 Sec#7/266 |
| From 52W High | -38.93% | US#2,446/3,121 Sec#190/266 |
| 1Y MDD | -52.88% | US#2,565/3,121 Sec#192/266 |
| Trading | ||
| Volume | 11,047,397 shares | US#267/3,121 Sec#20/266 |
| Trading Value | $195M | US#766/3,121 Sec#47/266 |
| Per Share | ||
| EPS | $-1.07 | US—/3,121 Sec—/266 |
| BPS | $0.79 | US#2,726/3,121 Sec#210/266 |
Company Info
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.